|
|
201 Mission Street, Suite #1380
San Francisco, CA 94105 USA
phone:(360) 668-3701
fax:
|
|
| Symbol |
Private |
| Founded |
2004 |
| Employees |
|
|
|
| www.jennerex.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development and commercialization of targeted oncolytic products for cancer |
|
| Management |
| David H. Kirn, Founder, President and Chief Executive Officer; Ian W. Malone, Chief Financial Officer; Patrick W. Trown, PhD, Senior Vice President, Development; John Bell, PhD, Chief Scientific Officer; Helena Chaye, PhD, LL.B., Vice President, Business Development and Operations. |
| |
|
|
| |
|
| Keywords |
| Cancer therapeutics, Vaccinia viruses, Radiotherapy, Cancer cell destruction. |
|
|
|
| Description |
|
Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of targeted oncolytic products for cancer. |
|
| Products / Services |
The Company?s lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.
Jennerex?s products target, attack and eradicate cancers through an oncolytic mechanism that is dependent on highly-specific replication of the Company?s poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer.
|
|
| Technology / Differentiation |
Jennerex engineers viruses to destroy cancer cells, but not normal cells. Jennerex's virus products target pathways that are commonly activated in most solid tumors including most lung, colon, breast and prostate cancers.
During a normal viral infection, a virus stimulates cellular activity so the virus can replicate itself. Jennerex's viruses are unable to do this in normal cells because we have deleted key viral genes. However, cancer cells are commonly activated in control pathways that can complement our viral gene deletions, so the Jennerex virus can still replicate in cancer cells and destroy them, even though they are attenuated in normal cells.
In addition, Jennerex's viruses express additional genes that help destroy cancer cells by other means, such as stimulating the body's immune system to rid itself of the cancer. So we attack the cancer in multiple ways, which is why it is less likely a cancer will become resistant to this treatment than to traditional therapies.
This "multi-pronged attack" also allows Jennerex's products to be effective against cancers that have failed standard therapies such as small molecules kinase inhibitors and chemotherapies. |
|
| Market / Customers |
Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members